Classys클래시스

Classys remains highly profitable on its filings, but its share price has fallen sharply over the past year.

Classys, a Korean maker of aesthetic medical devices sold mostly overseas, reported trailing twelve-month revenue of ₩369B and net income of ₩138B to H1 2026, with a 37.3% net margin. The share price closed at ₩27,200 on 26 October 2026, down 48.1% over one year and near its 52-week low of ₩26,550. The data does not explain the reason for the decline.

What stands out

• Revenue grew 38.6% in 2025 to about ₩337B, with operating margin of 50.7%, but trailing revenue to H1 2026 of ₩369B suggests growth has slowed since then.
• Free cash flow on a trailing basis was about ₩118B against net income of ₩138B, and the balance sheet shows ₩79B of cash against ₩147B of borrowings with liabilities at 39.6% of equity.
• Valuation has compressed: trailing P/E is 12.9 and P/B is 3.2, versus 26.9 and 6.4 at end-2025, and the DCF model's base value is ₩63,987, well above the current price, though this is a model output and not a forecast.
• Foreign ownership fell from 70.9% to 68.2% over about 60 days, while institutions were net sellers over the last 20 days, with foreign and retail buyers net positive.
• Recent filings are mostly investor relations event notices, plus a half-year report on 14 August 2026 and a 5%+ holding report on 3 September 2026. Headlines cover a senior hire and quarterly sales of ₩100B.

What to watch

• The next periodic results and any update to the earnings outlook, given that an earnings outlook was amended in August 2026.
• Whether revenue growth continues to slow after the strong 2025 year, since trailing revenue sits well below the 2025 growth pace.
• The August 2026 disclosure-related filings, including a non-designation as an insincere disclosure entity, and whether further filings explain the share price fall.